5 Einträge gefunden

1. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial

   1. Möbus, V
   2. Jackisch, C
   3. Lück, H J
   4. du Bois, A
   5. Thomssen, C
   6. Kuhn, W
   7. Nitz, U

   2018 - Forschungsinformationssystem des UKE
2. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.

   1. Mahner, S
   2. zu Eulenburg, Christine
   3. Staehle, A
   4. Wegscheider, K
   5. Reuss, A
   6. Pujade-Lauraine, E
   7. Harter, P

   2013 - Forschungsinformationssystem des UKE
3. Surgical intervention in relapsed ovarian cancer is beneficial: pro

   1. Harter, P
   2. Heitz, F
   3. Mahner, S
   4. Hilpert, F
   5. du Bois, A

   2013 - Forschungsinformationssystem des UKE
4. S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013

   1. Wagner, U
   2. Harter, P
   3. Hilpert, F
   4. Mahner, S
   5. Reuß, A
   6. du Bois, A
   7. Petru, E

   2013 - Forschungsinformationssystem des UKE
5. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer

   1. Harter, P
   2. Mahner, S
   3. Hilpert, F
   4. Runnebaum, I
   5. Ortmann, O
   6. Mustea, A
   7. Sehouli, J

   2013 - Forschungsinformationssystem des UKE